Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Re-enters Appetite Suppression Game With Thiakis Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Metabolic disorders is one of six focus areas targeted by Wyeth’s new discovery plan.
Advertisement

Related Content

Boehringer Enhances Diabetes Pipeline With Zealand's GLP-1/Glucagon Agonist
Boehringer Enhances Diabetes Pipeline With Zealand's GLP-1/Glucagon Agonist
Imperial Innovations Raises £140 Million To Invest In University Spin-Outs
Who Stays, Who Goes? Tricky Guessing On Wyeth/Pfizer’s Keeper Deals
Deals Of The Week: GSK/Dynavax, Wyeth Thiakis, Pfizer/Auxilium ...
Metabolic, Diabetes Landscape “Fertile Ground” For Partnerships
Can Big Pharma Save Biotech Investors?
Novartis Buys Protez For $100M
Sanofi Withdraws Zimulti NDA For Weight Loss
Sanofi Withdraws Zimulti NDA For Weight Loss

Topics

Advertisement
UsernamePublicRestriction

Register

PS067144

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel